FDA approves new drug Rocklatan to reduce intra-eye pressure in open-angle glaucoma or high-eye pressure patients

recent, the United StatesThe FDA(http://approved thenew drug(http://Rocklatan to reduce intra-eye pressure (IOP) in patients with open-angle glaucoma or hyper-eye pressureRocklatanRocklatan is a daily eye drop, consisting of 0.02% Ofarsuda (Netarsudil) and 0.005% Pga LatanoprostIn mercury 1 and MERCURY 2 two Phase 3 clinicaltrial(http://, Rocklatan reached the main end of the trial (90-day efficacy) and had a better single effect than Netarsudil and Latanoprost, with significant eye pressure reductionMore than 60 percent of patients reduced eye pressure by 30 percent or more, which was about twice as much as using Latanoprost aloneIn two MERCURY studies, patients treated with Rocklatan had the least systemic side effects, with more mild and tolerable eye adverse eventsamong, the most common adverse eye events are conjunctiva congestion, 90% of hyperemia patients are mild congestion, 5% of patients due to hyperemia and discontinuation of drugsOther common eye side effects reported in the study included pain at the drip site, conjunctiva bleeding, and so on